EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark TAVANTA THERAPEUTICS was filed as Word mark on 11/13/2020 at the European Union Intellectual Property Office.
It was registered as a trademark on 03/26/2021.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018338021 |
| Application date | November 13, 2020 |
| Publication date | December 17, 2020 |
| Entry date | March 26, 2021 |
| Expiration date | November 13, 2030 |
Trademark owner
70 Sir John Rogerson's Quay
2 Dublin
IE
2 Dublin
IE
Trademark representatives
Platform 94 Tech & Innovation Cluster Mervue Business Park
H91 D932 Galway City
IE
goods and services
5
Prescription pharmaceuticals for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals for treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex; pharmaceuticals exhibiting efficient drug release for the treatment of cancer, multiple sclerosis, cystic fibrosis, and tuberous sclerosis complex
42
Scientific, medical and pharmaceutical research and development, namely, development of new pharmaceutical formulations, development of pharmaceutical formulations for efficient drug release, development of clinical uses and treatments for new chemical entities and known pharmaceutical compounds; research and development of new pharmaceutical formulations; research and development of pharmaceutical formulations for efficient drug release; research and development of pharmaceuticals, namely, pharmaceuticals for treating cancer, multiple sclerosis, cystic fibrosis, tuberous sclerosis complex, and other disease states; research and development of new chemical entities and known pharmaceutical compounds; research and development of medicines, namely, for the treatment of cancer, multiple sclerosis, cystic fibrosis, tuberous sclerosis complex, and other disease states; scientific investigations for medical purposes; research and development of medicines, namely, new chemical entities and known pharmaceutical compounds
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| July 25, 2023 | Change Representative, Published | ||
| April 13, 2021 | Change Representative, Published | ||
| January 5, 2021 | Change Representative, Registered |
ID: 11018338021